CNS pipeline · person
Elissa Cote
Chief Corporate Development Officer of Vistagen since June 2025. Brings experience across small- to large-cap biopharma in strategic, transactional, and operational roles spanning neuropsychiatry and CNS; previously Chief Strategy and Business Development Officer at Sucampo Pharmaceuticals (acquired by Mallinckrodt).
- 1 company
Current roles
- Vistagen Therapeutics, Inc.Chief Corporate Development Officer · Executive2025–present
Appears with
People sharing a company with Elissa.
- Ann M. Cunningham · Vistagen Therapeutics, Inc.
- Cynthia L. Anderson · Vistagen Therapeutics, Inc.
- Gerard Sanacora · Vistagen Therapeutics, Inc.
- Gordon Keller · Vistagen Therapeutics, Inc.
- Joanne Curley · Vistagen Therapeutics, Inc.
- Jon S. Saxe · Vistagen Therapeutics, Inc.
- Joshua S. Prince · Vistagen Therapeutics, Inc.
- Margaret M. FitzPatrick · Vistagen Therapeutics, Inc.
- Mark Wallace · Vistagen Therapeutics, Inc.
- Mary L. Rotunno · Vistagen Therapeutics, Inc.
- Maurizio Fava · Vistagen Therapeutics, Inc.
- Michael R. Liebowitz · Vistagen Therapeutics, Inc.
- Reid G. Adler · Vistagen Therapeutics, Inc.
- Sanjay Mathew · Vistagen Therapeutics, Inc.
- Shawn K. Singh · Vistagen Therapeutics, Inc.
- Thomas Laughren · Vistagen Therapeutics, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.